This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Geron's Imetelstat Gets Fast Track Status for Myelofibrosis
by Zacks Equity Research
Geron's (GERN) sole pipeline candidate, imetelstat, receives Fast Track designation from the FDA for treating relapsed or refractory myelofibrosis. Shares up.
Celgene (CELG) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Celgene (CELG) closed at $99.30 in the latest trading session, marking a +0.46% move from the prior day.
Incyte (INCY) Stock Up 16% YTD on Strong Jakafi Performance
by Zacks Equity Research
Incyte (INCY) outperforms the industry on strong performance of Jakafi and encouraging pipeline progress.
Celgene (CELG) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Celgene (CELG) closed at $99.42, marking a +0.05% move from the previous day.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Sweta Killa
Sector ETF report for PBE
3 Big Biotech Stocks Worth Adding to Your Portfolio Now
by Ekta Bagri
We highlight a few key biotech stocks that surpass the sector so far in 2019 and are likely to witness a winning run in the near term.
Acceleron Discontinues Mid-Stage Muscular Dystrophy Study
by Zacks Equity Research
Acceleron Pharma's (XLRN) pipeline candidate, ACE-083, fails to translate muscle volume growth into improvements in functional tests in FSHD patients. Acceleron discontinues development.
Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates, acquisition deals, and more.
Celgene (CELG) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Celgene (CELG) closed at $98.60, marking a +0.22% move from the previous day.
Karyopharm Signs $150M Royalty Agreement to Support Xpovio
by Zacks Equity Research
Karyopharm (KPTI) signs royalty agreement with HealthCare Royalty Partners for up to $150 million to fund Xpovio's commercialization and development.
The Zacks Analyst Blog Highlights: Celgene, Sinopec, HSBC, Vertex Pharmaceuticals and Prudential Financial
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Sinopec, HSBC, Vertex Pharmaceuticals and Prudential Financial
Amgen's Kyprolis Combo Improves PFS in Multiple Myeloma Study
by Zacks Equity Research
Amgen's (AMGN) phase III study on Kyprolis in combination with dexamethasone and J&J's Darzalex meets the goal of progression-free survival for treating relapsed or refractory multiple myeloma.
Top Stock Reports for Celgene, Sinopec & HSBC
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Celgene (CELG), Sinopec (SNP) and HSBC Holdings (HSBC).
Celgene's (CELG) Leukemia Candidate Meets Endpoints in Study
by Zacks Equity Research
Celgene's (CELG) CC-486 maintenance therapy improves overall survival in newly-diagnosed acute myeloid leukemia patients.
J&J's Ponesimod Superior to Aubagio in Relapsing MS Patients
by Zacks Equity Research
J&J (JNJ) announces superiority of its multiple sclerosis candidate, ponesimod compared to Sanofi's Aubagio in patients with relapsing form of the disease.
Celgene (CELG) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Celgene (CELG) closed at $98.41, marking a +0.78% move from the previous day.
FDA Grants Orphan Drug Status to Acceleron's PAH Candidate
by Zacks Equity Research
The FDA assigns an orphan drug status to Acceleron's (XLRN) investigational therapy sotatercept for the treatment of patients with pulmonary arterial hypertension. Shares inch up.
Roche's Tecentriq Combo Gets EU Nod for Difficult Lung Cancer
by Zacks Premium Research
The latest EU nod makes Roche's (RHHBY) immuno-oncology drug -- Tecentriq -- the first and only cancer immunotherapy approved for the initial treatment of ES-SCLC in Europe.
Celgene (CELG) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Celgene (CELG) closed the most recent trading day at $97.43, moving +0.47% from the previous trading session.
Roche Extends Offer to Acquire Spark Therapeutics Yet Again
by Zacks Equity Research
Roche's (RHHBY) acquisition of Spark Therapeutics gets delayed once again to allow the FTC more time for review.
Top-Performing Biotech ETFs YTD
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to boost the biotech stocks. Accordingly, we take a look at biotech ETFs gaining more than 10% year to date.
5 Cancer-Fighting Stocks to Add to Your Portfolio
by Zacks Equity Research
Cancer-fighting stocks receive a boost from advance research and development. These five stocks can add value to your portfolio.
Celgene (CELG) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Celgene (CELG) closed at $96.80, marking a -0.32% move from the previous day.
Roche's Tecentriq Combo Gets EU Nod for Critical Breast Cancer
by Zacks Equity Research
Roche (RHHBY) wins EU approval for its immuno-oncology drug Tecentriq in combination with Abraxane to treat metastatic triple-negative breast cancer, which is a difficult-to-treat disease.
Geron (GERN) Stock Rises 40% in 2019 So Far: Here's Why
by Zacks Equity Research
Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late-stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.